On 1 August 2024, Pharmacy Daily reported that Bristol Myers Squibb’s (BMS) Opdivo® (nivolumab) has had a new indication for resectable non-small cell lung cancer (NSCLC) listed on Australia’s Pharmaceutical Benefits Scheme (PBS). It now joins MSD’s Keytruda® (pembrolizumab) in being listed on the PBS for treating NSCLC.
As previously reported, the application for this listing was considered at the Pharmaceutical Benefits Assessment Committee (PBAC) meeting in March 2024. BMS has also applied to have Opdivo® and Yervoy® (ipilimumab) listed for unresectable malignant mesothelioma.